| Literature DB >> 20340016 |
Bernd Kubista1, Florian Klinglmueller, Martin Bilban, Martin Pfeiffer, Richard Lass, Alexander Giurea, Phillipp T Funovics, Cyril Toma, Martin Dominkus, Rainer Kotz, Theresia Thalhammer, Klemens Trieb, Teresa Zettl, Christian F Singer.
Abstract
Osteosarcoma is the most common primary malignant bone tumour. Currently osteosarcoma classification is based on histological appearance. It was the aim of this study to use a more systematic approach to osteosarcoma classification based on gene expression analysis and to identify subtype specific differentially expressed genes. We analysed the global gene expression profiles of ten osteosarcoma samples using Affymetrix U133A arrays (five osteoblastic and five non-osteoblastic osteosarcoma patients). Differential gene expression analysis yielded 75 genes up-regulated and 97 genes down-regulated in osteoblastic versus non-osteoblastic osteosarcoma samples, respectively. These included genes involved in cell growth, chemotherapy resistance, angiogenesis, steroid- and neuropeptide hormone receptor activity, acute-phase response and serotonin receptor activity and members of the Wnt/ß-catenin pathway and many others. Furthermore, we validated the highly differential expression of six genes including angiopoietin 1, IGFBP3, ferredoxin 1, BMP, decorin, and fibulin 1 in osteoblastic osteosarcoma relative to non-osteoblastic osteosarcoma. Our results show the utility of gene expression analysis to study osteosarcoma subtypes, and we identified several genes that may play a role as potential therapeutic targets in the future.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20340016 PMCID: PMC3047650 DOI: 10.1007/s00264-010-0996-6
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075